Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

Benzinga Newsdesk www.benzinga.com Positive 72.5%

Neg 0% Neu 0% Pos 72.5%

Jefferies analyst Anthea Li assumes Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and lowers Price Target of $48.

Comments

No comments yet. Be the first!